This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%

Core Insights - Baker Bros. Advisors disclosed a purchase of 455,208 shares of GRAIL, valued at approximately $39.33 million based on the average price during Q4 2025 [1][2] - The value of GRAIL's position increased by $82.09 million due to the acquisition of additional shares and stock price changes, representing about 1% of Baker Bros. Advisors' assets [2] Company Overview - GRAIL is a biotechnology company focused on advanced diagnostics for early cancer detection, utilizing proprietary technology to meet significant needs in oncology screening and diagnosis [6] - The company aims to improve patient outcomes and establish a leadership position in the medical diagnostics market [6] Financial Metrics - GRAIL's market capitalization is $1.6 billion, with a revenue of $141.83 million and a net income of -$406.24 million for the trailing twelve months [4] - As of February 17, 2026, GRAIL's stock price was $42.22, reflecting a 4% increase over the past year, although it underperformed compared to the S&P 500's 13% gain [8] Revenue Performance - GRAIL's fourth-quarter revenue rose by 14% to $43.6 million, while full-year revenue increased by 17% to $147.2 million [11] - U.S. Galleri revenue reached $136.8 million for the year, marking a 26% increase, with over 185,000 Galleri tests sold in 2025 [11] Product and Market Focus - GRAIL develops early cancer detection technologies, including the Galleri multi-cancer screening test and DAC diagnostic aid, and is expanding into minimal residual disease and post-diagnostic testing [9] - The company primarily generates revenue through the sale of diagnostic tests and screening services to healthcare providers, targeting asymptomatic individuals over 50 and healthcare systems [9] Market Challenges - The NHS-Galleri trial did not achieve a statistically significant reduction in Stage III to IV cancers, despite improvements in earlier-stage detection, leading to a nearly 60% decline in stock price following the report [12] - Long-term investors should monitor regulatory traction, commercial adoption, and cash burn relative to the cash runway, as the future of Galleri's standard of care remains uncertain [13]